Logo image of ONCY

ONCOLYTICS BIOTECH INC (ONCY) Stock Fundamental Analysis

NASDAQ:ONCY - Nasdaq - CA6823108759 - Common Stock - Currency: USD

0.561  -0.01 (-1.23%)

After market: 0.55 -0.01 (-1.96%)

Fundamental Rating

1

Taking everything into account, ONCY scores 1 out of 10 in our fundamental rating. ONCY was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of ONCY have multiple concerns. ONCY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONCY has reported negative net income.
ONCY had a negative operating cash flow in the past year.
ONCY had negative earnings in each of the past 5 years.
ONCY had a negative operating cash flow in each of the past 5 years.
ONCY Yearly Net Income VS EBIT VS OCF VS FCFONCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -157.08%, ONCY is doing worse than 85.04% of the companies in the same industry.
ONCY has a worse Return On Equity (-530.00%) than 79.75% of its industry peers.
Industry RankSector Rank
ROA -157.08%
ROE -530%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ONCY Yearly ROA, ROE, ROICONCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCY Yearly Profit, Operating, Gross MarginsONCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONCY has more shares outstanding
The number of shares outstanding for ONCY has been increased compared to 5 years ago.
ONCY has a worse debt/assets ratio than last year.
ONCY Yearly Shares OutstandingONCY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ONCY Yearly Total Debt VS Total AssetsONCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -35.49, we must say that ONCY is in the distress zone and has some risk of bankruptcy.
ONCY has a worse Altman-Z score (-35.49) than 91.73% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that ONCY is not too dependend on debt financing.
ONCY has a Debt to Equity ratio of 0.13. This is in the lower half of the industry: ONCY underperforms 67.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -35.49
ROIC/WACCN/A
WACCN/A
ONCY Yearly LT Debt VS Equity VS FCFONCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

ONCY has a Current Ratio of 2.82. This indicates that ONCY is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.82, ONCY is not doing good in the industry: 67.25% of the companies in the same industry are doing better.
A Quick Ratio of 2.82 indicates that ONCY has no problem at all paying its short term obligations.
With a Quick ratio value of 2.82, ONCY is not doing good in the industry: 65.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.82
Quick Ratio 2.82
ONCY Yearly Current Assets VS Current LiabilitesONCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ONCY have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ONCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.46%
EPS Next 2Y-1.41%
EPS Next 3Y5.64%
EPS Next 5Y39.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCY Yearly Revenue VS EstimatesONCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ONCY Yearly EPS VS EstimatesONCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCY Price Earnings VS Forward Price EarningsONCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCY Per share dataONCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.41%
EPS Next 3Y5.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONCY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLYTICS BIOTECH INC

NASDAQ:ONCY (4/17/2025, 8:00:02 PM)

After market: 0.55 -0.01 (-1.96%)

0.561

-0.01 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-07 2025-03-07/bmo
Earnings (Next)05-02 2025-05-02/amc
Inst Owners1.63%
Inst Owner Change0.39%
Ins Owners3.89%
Ins Owner ChangeN/A
Market Cap44.89M
Analysts80
Price Target3.2 (470.41%)
Short Float %3.87%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.7%
Min EPS beat(2)-15.35%
Max EPS beat(2)18.74%
EPS beat(4)3
Avg EPS beat(4)6%
Min EPS beat(4)-15.35%
Max EPS beat(4)18.74%
EPS beat(8)5
Avg EPS beat(8)9.64%
EPS beat(12)8
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)8.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.62%
PT rev (3m)-29.9%
EPS NQ rev (1m)9.09%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)18.51%
EPS NY rev (3m)16.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.42
P/tB 10.42
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -157.08%
ROE -530%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-83.59%
ROE(3y)-241.47%
ROE(5y)-177.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.37%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.82
Quick Ratio 2.82
Altman-Z -35.49
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.58%
Cap/Depr(5y)28.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y1.46%
EPS Next 2Y-1.41%
EPS Next 3Y5.64%
EPS Next 5Y39.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.93%
EBIT Next 3Y4.05%
EBIT Next 5Y42.91%
FCF growth 1Y4.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.21%
OCF growth 3YN/A
OCF growth 5YN/A